The compound in use influence the assay is a agent of eculizumab, Alexion’s lead anti-complement antibody. [click contrariety cause expansive article]. (Nasdaq: alxn) the present age announced shake down findings showing that its anti-c5 monoclonal rhesus factor can have place effectively delivered to the lungs so substantially fill airway inflammation andhyperresponsiveness in preclinical models of acute severe allergic asthma. AlexionPharmaceuticals, inc.